Following a $55 million venture financing, drug developer Versartis Inc. filed Tuesday for an $80 million IPO. The Redwood City company, whose lead drug is a long-acting recombinant human growth hormone targeting children, is designed to reduce the number of daily injections that patients must receive. Versartis, led by CEO Jeffrey Cleland, is the third Bay Area life sciences company — after KineMed Inc. and Achaogen Inc. — to file for an initial public offering already this year.
Help employers find you! Check out all the jobs and post your resume.
